Guardant Health (Nasdaq:GH) - Stock Price, News & Analysis

GH Stock Overview

A precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.

About the company

GH fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 29.6% below our estimate of its fair value

Revenue is forecast to grow 16.4% per year

Analysts in good agreement that stock price will rise by 59.7%

Risk Analysis

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Guardant Health, Inc. Competitors

Privia Health Group

NasdaqGS:PRVA

US$2.5b

LifeStance Health Group

NasdaqGS:LFST

US$2.4b

Astrana Health

NasdaqCM:ASTH

US$2.4b

R1 RCM

NasdaqGS:RCM

US$5.9b

Price History & Performance

Summary of all time highs, changes and price drops for Guardant Health
Historical stock prices
Current Share Price	US$26.74
52 Week High	US$41.06
52 Week Low	US$15.81
Beta	1.13
11 Month Change	-18.97%
3 Month Change	2.22%
1 Year Change	-30.04%
33 Year Change	-78.81%
5 Year Change	-69.45%
Change since IPO	-16.96%

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Recent updates

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Jul 31

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 12

Guardant: Double-Digit Sales Projections Come At A Cost

Jun 06

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Jun 04

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

May 14

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21

Shareholder Returns

	GH	US Healthcare	US Market
7D	-5.8%	1.2%	0.1%
1Y	-30.0%	13.9%	24.9%

Return vs Industry: GH underperformed the US Healthcare industry which returned 14.1% over the past year.

Return vs Market: GH underperformed the US Market which returned 25.9% over the past year.

Price Volatility

Is GH's price volatile compared to industry and market?
GH volatility
GH Average Weekly Movement	9.0%
Healthcare Industry Average Movement	7.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: GH's share price has been volatile over the past 3 months.

Volatility Over Time: GH's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2011	1,774	Helmy Eltoukhy	guardanthealth.com

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.

Guardant Health, Inc. Fundamentals Summary

How do Guardant Health's earnings and revenue compare to its market cap?
GH fundamental statistics
Market cap	US$3.57b
Earnings (TTM)	-US$490.76m
Revenue (TTM)	US$643.81m

5.1x

P/S Ratio

-6.7x

P/E Ratio

Is GH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GH income statement (TTM)
Revenue	US$643.81m
Cost of Revenue	US$257.85m
Gross Profit	US$385.96m
Other Expenses	US$876.72m
Earnings	-US$490.76m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-3.99
Gross Margin	59.95%
Net Profit Margin	-76.23%
Debt/Equity Ratio	-70,753.6%

How did GH perform over the long term?

See historical performance and comparison

GH Stock Overview

Rewards

Risk Analysis

Guardant Health, Inc. Competitors

NasdaqGS:PRVA

US$2.5b

NasdaqGS:LFST

US$2.4b

NasdaqCM:ASTH

US$2.4b

NasdaqGS:RCM

US$5.9b

Price History & Performance

Recent News & Updates

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Price target increased by 7.0% to US$41.85

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

Recent updates

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Price target increased by 7.0% to US$41.85

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

High number of new directors

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Guardant: Double-Digit Sales Projections Come At A Cost

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Price target decreased by 7.1% to US$42.94

Full year 2023 earnings: EPS misses analyst expectations

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Guardant Health, Inc. to Appeal Federal District Court Verdict

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Now 20% undervalued after recent price drop

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 7.1% to US$52.82

Guardant Health, Inc. Announces Management Changes

Chief Legal Officer exercised options and sold US$90k worth of stock

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

High number of new directors

Co-CEO & Director recently bought US$2.5m worth of stock